This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Donnelly, R. Search for Related Content Social Bookmarking                         What's this?

Review: Managing cardiovascular risk in patients with diabetes

The Medical School, Derby City General Hospital, Uttoxeter Road, Derby, DE22 3DT, UK, richard.donnelly{at}nottingham.ac.uk

The increasingly large number of patients with diabetes in the UK are at greatly increased risk of cardiovascular disease, including coronary heart disease and stroke, compared to the general population. Many diabetes patients exhibit metabolic syndrome and these additional risk factors, such as raised hypertension and cholesterol, multiply the overall risk. Reducing these risk factors to target levels is essential and requires a multifactorial approach. Lifestyle changes, tight glycaemic control, antiplatelet drugs (aspirin) and control of lipid levels, e.g. using statins, can all have significant beneficial effects. Blood pressure control is another vital aspect in reducing risk and a number of recent studies have provided evidence supporting the use of angiotensin-converting enzyme inhibitors as first-line treatment in patients with diabetes.

Key Words: ACE inhibitor • cardiovascular disease • diabetes • hypertension • metabolic syndrome.

References

• Diabetes in the UK 2004: Diabetes UK, 2004: 1-27.
• Chan JC, Cheung JC, Stehouwer CD et al. The central roles of obesity associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome - an analaysis by structural equation modelling. Int J Obes Realt Metab Disord 2002;26:994-1008.[CrossRef]
• Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
• Alberti KGM, Zimmet, P., Shaw J., for the IDF Epidemiology Task Force Consensus Group. Lancet 2005;366:1059-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005.
• Yki-Järvinen H. The PROactive study: some answer, many questions. Lancet 2005;366:1241-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dormandy J., Charbonnel B., Eckland D. et al. On behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in microVascular Events): a randomized controlled clinical trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268:1292-300.[Abstract/Free Full Text]
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• MRC/BHF Heart PRotection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Williams B., Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Strippoli GF, Craig M., Deeks JJ, Schena FP, Craig JC Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828.[Abstract/Free Full Text]
• Lindholm LH, Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
• Dahlof B., Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fox KM Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R., Simoons ML The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005;26:1369-78.[Abstract/Free Full Text]
• Mogensen CE, Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.[Abstract/Free Full Text]
• Doulton TW, He FJ, MacGregor GA Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005;45:880-6.[Abstract/Free Full Text]
• Braunwald E., Domanski MJ, Fowler SE et al. Angiotensin-convertingenzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-68.[Abstract/Free Full Text]
• Pilote L., Abrahamowicz M., Rodrigues E., Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004;141:102-12.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 6, 325-329 (2005)
DOI: 10.1177/14746514050050060501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. W Mccallum and M. Fisher Review: Comparing cardiovascular outcomes in diabetes studies The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 111 - 118. [Abstract] [PDF]

				J. P Vora Editorial The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2_suppl): S1 - S1. [PDF]

				M. Fisher and I. W Campbell Residual cardiovascular risk and practical management of type 2 diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2_suppl): S17 - S23. [Abstract] [PDF]

				A. J Krentz Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 303 - 304. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Donnelly, R. Search for Related Content Social Bookmarking                         What's this?